Proteomics and Bioanalysis

proteomics and bioanalysis expertise.

The Proteomics and Bioanalysis Core (PBC) services Fortune 500 companies, such as Merck and Johnson & Johnson. It operates as a collaborative core, developing analytical strategies that address significant bioanalytical challenges and thereby advance knowledge in a variety of applications.

The PBC specializes in proteomics, LC/MS (liquid chromatography–mass spectrometry) and bioinformatics. The facility includes a well-equipped wet-lab devoted to cell culture, biochemistry experiments (for Western-blotting, electrophoresis, ELISA, etc.), column packing, treatment of proteomic samples and preparation for quantitative analysis. Through our business-friendly approach, we will work with you to deliver the results you need to grow.

We partner with industry to offer:

  • targeted protein quantification
  • proteomics analysis of biological samples
  • targeted small molecule/metabolite quantification
  • de novo sequencing of target proteins
Jun Qu.
Faculty Spotlight: Jun Qu, PhD, Department of Pharmaceutical Sciences at SUNY Buffalo

Qu recieved his Ph.D in Analytical Chemistry at Tsinghua University, Beijing, China, in 2002. His interests are in Proteomics and Pharmaceutical Analysis, and his research programs in the proteomics field involve: i) High-resolution and large-scale expression profiling of pathological proteomes (e.g. for cardiovascular diseases, colon cancer and infectious diseases, HIV, COPD, etc) for the discovery of disease/therapeutic biomarkers by gel-free LC/MS methods; ii) Sensitive identification, localization and quantification of post-translational modifications in complex proteomes, with the emphases on arginine methylation and phosphorylation. Novel anti-PTM-peptides capture procedure and alternating collision induced dissociation (CID)/electron transferring dissociation (ETD) are employed to obtain abundant PTM information; iii) Targeted quantification of regulatory, marker proteins for clinical study.